This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nichols, K. E. Articles by Diller, L. Search for Related Content PubMed PubMed Citation Articles by Nichols, K. E. Articles by Diller, L. Social Bookmarking                            What's this?

TP53, BRCA1, and BRCA2 Tumor Suppressor Genes Are Not Commonly Mutated in Survivors of Hodgkin’s Disease With Second Primary Neoplasms

Kim E. Nichols, John A. Heath, Debra Friedman, Jaclyn A. Biegel, Arupa Ganguly, Peter Mauch, Lisa Diller

From the Departments of Pediatric Oncology and Human Genetics, Children’s Hospital of Philadelphia; Department of Genetics, University of Pennsylvania, Philadelphia, PA; Departments of Pediatric Oncology and Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Pediatric Hematology/Oncology, Children’s Hospital and Medical Center, Seattle, WA.

Address reprint requests to Lisa Diller, MD, Pediatric Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115; e-mail: lisa_diller{at}dfci.harvard.edu.

Purpose: Despite recognition that second malignant neoplasms (SMNs) contribute significantly to mortality after the successful treatment of Hodgkin’s disease (HD), little is known about the molecular events leading to secondary tumors. Factors contributing to second cancer risk include the carcinogenic effects of ionizing radiation and chemotherapy, in combination with possible host susceptibility. To clarify whether host genetic factors contribute to secondary tumorigenesis, we performed mutational analyses of the TP53, BRCA1, and BRCA2 tumor suppressor genes in a cohort of 44 HD patients developing one or more SMN.

Patients and Methods: Family cancer histories and constitutional DNA samples were obtained from 44 HD patients with SMNs identified. Using DNA-based sequencing, we evaluated the TP53 gene in all 44 patients. Nineteen female patients developing one or more secondary breast cancer were also analyzed for mutations in the BRCA1 and BRCA2 breast cancer–susceptibility genes.

Results: Nineteen patients (43%) had more than one SMN, and 12 patients (27%) had a positive family history of cancer. One of 44 patients tested for TP53 harbored a novel homozygous germline abnormality. One of 19 patients tested for BRCA2 carried a previously described heterozygous inactivating mutation. We identified no germline BRCA1 mutations.

Conclusion: Despite features suggestive of genetic predisposition, the TP53, BRCA1, and BRCA2 genes were not frequently mutated in this cohort of HD patients developing SMNs. Larger studies of these genes or investigations of other genes involved in cellular DNA damage response pathways may identify host genetic factors that contribute to secondary tumorigenesis.

Supported in part by grants from the David B. Perini Jr Quality of Life Program (L.D.) and the Lee Family Fellowship (K.E.N.), Dana-Farber Cancer Institute, Boston, MA.

Both K.E.N. and J.A.H. contributed equally to this work.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. Andrieu, D. F. Easton, J. Chang-Claude, M. A. Rookus, R. Brohet, E. Cardis, A. C. Antoniou, T. Wagner, J. Simard, G. Evans, et al. Effect of Chest X-Rays on the Risk of Breast Cancer Among BRCA1/2 Mutation Carriers in the International BRCA1/2 Carrier Cohort Study: A Report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group J. Clin. Oncol., July 20, 2006; 24(21): 3361 - 3366. [Abstract] [Full Text] [PDF]